Alnylam Execs Downplay Importance of Silence Therapeutics' Zamore IP

During a conference call held to discuss Alnylam's second-quarter financial results, the company also provided some details on its biologics manufacturing initiative.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories